Leptin and the ob-receptor as anti-obesity target: Recent in silico advances in the comprehension of the protein-protein interaction and rational drug design of anti-obesity lead compounds

Current Pharmaceutical Design

Volumn 20, Issue 1, 2014, Pages 136-145

  Tutone, Marco ^a   Lauria, Antonino ^a   Almerico, Anna Maria ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Homology modelling; Leptin; Leptin receptor; Leptin receptor agonists antagonists; Molecular modelling; Obesity; Protein protein docking

Indexed keywords

ANTIOBESITY AGENT; LEPTIN; LEPTIN RECEPTOR;

ARTICLE; COMPUTER MODEL; DRUG DESIGN; DRUG MECHANISM; DRUG TARGETING; HUMAN; MOLECULAR MODEL; OBESITY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; RISK FACTOR; SIGNAL TRANSDUCTION; WEIGHT CONTROL; BODY WEIGHT; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; NEWBORN; PROTEIN BINDING; REVIEW;

ANTI-OBESITY AGENTS; BODY WEIGHT; DRUG DESIGN; HUMANS; INFANT, NEWBORN; LEPTIN; MODELS, MOLECULAR; OBESITY; PROTEIN BINDING; RECEPTORS, LEPTIN; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84902880818     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113196660743     Document Type: Article

References (92)

1. Obesity and Overweight available on http://www.who.int/mediacentre/factsheets/fs311/en/
2. Global status report on noncommunicable diseases 2010. available on http://www.who.int/nmh/publications/ncd_report_full_en.pdf
3. World Health Organization. Obesity: Preventing and managing the global epidemic. Report of a WHO consultation on obesity June 3-5, 1997. Geneva, Switzerland. Publication WHO/NUT/NCD/98.1.
4. Kushner R, Roth J. Assessment of the obese patient. Endocrinol Metab Clin North Am. 2003; 32: 915-33.
5. Heshka J, Jones P. A role for dietary fat in leptin receptor, Ob-Rb, function. Life Sci 2001; 69: 69987-1003.
6. Lonnqvist F, Arner P, Nordfors L, Shalling M. Overexpression of the obese (ob) gene in adipose tissue of human obese subjects. Nat Med 1995; 1: 950-3.
7. Misra A, Garg A. Leptin, its receptor and obesity. J Invest Med 1996; 44: 535-48.
8. Banks WA, Kastin AJ, Huang AW, Jasgan JB, Naness LH. Leptin enters the brain by a saturable system independent of insulin. Peptides 1996; 17: 305-11.
9. Caro JF, Kolaczynski JW, Nyce MR, et al. Decreased cerebrospinal fluid/serum leptin ratio in obesity: A possible mechanism for leptin resistance. Lancet 1996; 348: 159-61.
10. Fruhbeck G. A heliocentric view of leptin. Proc Nutr Soc 2001; 60: 301-18.
11. Zhang FM, Basinski MJ, Beals J, et al. Crystal structure of the obese protein leptin-E100. Nature 1997; 387: 206-9.
12. Gertler A. Development of leptin antagonists and their potential use in experimental biology and medicine, TRENDS in Endocrin and Metab 2006; 17: 372-8.
13. Zhang Y., Proenca R, Friedman JM, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-32.
14. Tartaglia LA, Dembski M, Weng X, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995; 83: 1263-71.
15. Haniu M, Arakawa T, Bures E J Y. et al. Human leptin receptor. Determination of disulfide structure and N-glycosylation sites of the extracellular domain, J Biol Chem 1998; 273: 28691-99.
16. Fong TM, Huang RR, Tota MR, et al. Localization of leptin binding domain in the leptin receptor. Mol Pharmacol 1998; 53: 234-40.
17. Ghilardi N, Skoda RC. The leptin receptor activates janus kinase 2 and signals for proliferation in a factor-dependent cell line. Molecular Endocrinology 1997; 11: 393-9.
18. Baumann H, Morella KK, White DW, et al. The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc Nat Acad Sci USA 1993; 93: 8374-8.
19. Bjorbaek C, Uotani S, Da Silva B, Flier JS. Divergent signaling capabilities of the long and short isoforms of the leptin receptor. J Biol Chem 1997; 272: 32686-95.
20. Tartaglia LA. The leptin receptor. J Biol Chem 1997; 272: 6093-6.
21. Ghilardi N, Ziegler S, Wiestner A, et al. Defective STAT signaling by the leptin receptor in diabetic mice. Proc Nat Acad Sci USA 1996; 93: 6231-5.
22. Hiroike T, Higo J, Jingami H, Toh H. Homology Modeling of Human Leptin/Leptin Receptor Complex. Biochem Biophys Res Comm 2000; 275: 154-8.
23. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22: 4673-80.
24. Morikami K, Nakai T, Kidera A, Saito M, Nakamura H. PRESTO: A Vectorized Molecular Mechanics Program for Biopolymers. Computers Chem 1992; 16: 243-8.
25. Cornell WD, Cieplak PR, Bayly CI, et al. A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules J Am Chem Soc 1995; 117: 5179-97.
26. Ding HQ, Karasawa N, Goddard WA. Atomic level simulationson a million particles-the cell multipole method for Coulomb and London nonbond interactions J Chem Phys 1992; 97: 4309-15.
27. Shrake A, Rupley J A. Environment and exposure to solvent of protein atoms. J Mol Biol 1973; 79: 351-71.
28. Bogan AA, Thorn KS, Anatomy of hot spots in protein interfaces. J Mol Biol 1998; 280: 1-9.
29. Imagawa K, Numata Y, Katsuura G, et al. Structure-function studies of human leptin. J Biol Chem 1998; 273: 35245-9.
30. Verploegen S, Plaetinck G, Devos R, Van der Hyden J, Guisez, Y. A human leptin mutant induces weight gain in normal mice. FEBS Lett 1997; 405: 237-40.
31. Sandowski Y, Raver N, Gussakovsky EE, et al. Subcloning, expression, purification, and characterization of recombinant human leptin-binding domain. J Biol Chem 2002; 277: 46304-9.
32. Jones TA, Zou JY, Cowan SW, Kjeldgaard MW. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr Sect A 1991; 47: 110-9.
33. Brunger AT, Adams PD, Clore GM, et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr Sect D Biol Crystallogr 1998; 54: 905-21.
34. Livnahì O, Stura EA, Johnson DL, et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 1996; 273: 464-71.
35. De Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 1992; 255: 306-12.
36. Clackson T, Wells JA. A Hot Spot of Binding Energy in a Hormone-Receptor Interface. Science 1995; 267: 383-6.
37. Baumgartner JW, Wells CA, Chen CM, Waters, MJ. The role of the WSXWS equivalent motif in growth hormone receptor function. J Biol Chem 1994; 269: 29094-100.
38. Peelman F, Van Beneden K, Zabeau L, et al. Mapping of the leptin binding sites and design of a leptin antagonist. J Biol Chem 2004; 279: 41038-46.
39. Peelman F, Iserentant H, Eyckerman S, Zabeau L, Tavernier, J. Leptin, immune responses and autoimmune disease. Perspective on the use of leptin. Curr Pharm Des 2005; 11: 539-48.
40. Chow DC, He XL, Snow AL, Rose-John S, Garcia, KC. Structure of an extracellular gp130 cytokine receptor signaling complex. Science 2001; 291: 2150-5.
41. Aritomi M, Kunishima N, Okamoto T, Kuroki R, Ota Y, Morikawa K. Atomic structure of the GCSF-receptor complex showing a new cytokine-receptor recognition scheme. Nature 1999; 401: 713-8.
42. Elkins PA, Christinger HW, Sandowski Y, Sakal E, Gertler A, de Vos AM, Kossiakoff AA. Nat Struct Biol 2000; 7: 808-15.
43. Kalai M, MonteroJulian FA, Grotzinger J, et al. Analysis of the Human Interleukin-6/Human Interleukin-6 Receptor Binding Interface at the Amino Acid Level: Proposed Mechanism of Interaction. Blood 1997; 89: 1319-33.
44. Bravo J, Heath JK. Receptor recognition by gp130 cytokines EMBO J 2000; 19: 2399-411.
45. Zabeau L, Defeau D, Van der Heyden J, et al. Functional analysis of leptin receptor activation using a Janus kinase/signal transducer and activator of transcription complementation assay. Mol Endocrinol 2004: 18: 150-61.
46. Iserentant H, Peelman F, Defeau D, et al. Mapping of the interface between leptin and the leptin receptor CRH2 domain. J Cell Sci 2005; 118: 2519-27.
47. http://www.ebi.ac.uk/dali/
48. Notredame C, Higgins DG, Heringa J. T-Coffee: A novel method for fast and accurate multiple sequence alignment. J Mol Biol 2000; 302: 205-17.
49. Xiang Z, Soto CS, Honig B. Evaluating conformational free energies: the colony energy and its application to the problem of loop prediction Proc Natl Acad Sci USA 2002; 99: 7432-37.
50. Jackson RM, Gabb HA, Sternberg MJ. Rapid refinement of protein interfaces incorporating solvation: application to the docking problem. J Mol Biol 1998; 276: 265-85.
51. http://www.biochem.ucl.ac.uk/bsm/PP/server/
52. Gonzalez RR, Leavis PC. A peptide derived from the human leptin molecule is a potent inhibitor of the leptin receptor function in rabbit endometrial cells. Endocrine 2003; 21: 185-95.
53. Peelman F, Iserentant H, De Smet AS, et al. Mapping of binding site III in the leptin receptor and modeling of a hexameric leptinleptin receptor complex. J. Biol Chem 2006; 281: 15496-504.
54. Bairoch A, Apweiler R, Wu CH, et al. Nucleic Acids Res 2005; 33: D154-D159.
55. Altschul SF, Madden TL, Schaffer AA, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997; 25: 3389-402.
56. Holm L, Sander C. The FSSP database: fold-based on structurestructure alignment of proteins. Nucleic Acids Res 1996; 24: 206-9.
57. Bateman A, Coin L, Durbin R, et al. The Pfam protein families database. Nucleic Acids Res 2004; 32: D138-D141.
58. Marchler-Bauer A, Anderson JB, Cherukuri PF, et al. CDD: a Conserved Domain Database for protein classification. Nucleic Acids Res 2005; 33: D192-D196.
59. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993; 234: 779-815.
60. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. Hexameric structure and assembly of the interleukin-6/IL-6 alphareceptor/gp130 complex. Science 2003; 300: 2101-4.
61. Niv-Spector L, Gonen-Berger D, Gourdou I, et al. Identification of the hydrophobic strand in the A-B loop of leptin as major binding site III: implications for largescale preparation of potent recombinant human and ovine leptin antagonists. Biochem J 2005; 391: 221-30.
62. Carpenter B, Hemsworth GR, Wu Z, Maamra M, Strasburger CJ, Ross RJ, Artymiuk PJ. Structure of the human obesity receptor leptin-binding domain reveals the mechanism of leptin antagonism by a monoclonal antibody. Structure 2012; 20: 487-97.
63. Fazeli M, Zarkesh-Esfahani H, Wu Z, et al. Identification of a monoclonal antibody against the leptin receptor that acts as an antagonist and blocks human monocyte and T cell activation. J Immunol Methods 2006; 312: 190-200.
64. Teplyakov A, Obmolova G, Malia T, Gilliland G. Antigen recognition by antibody C836 through adjustment of VL/VH packing Acta Crystallogr Sect F Struct Biol Cryst Commun 2011; 67: 1165-7.
65. Tovchigrechko A, Vakser IA. GRAMM-X public web server for protein-protein docking. Nucleic Acids Res 2006; 34: Web Server issue, W310-4.
66. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 1997; 18: 2714-23.
67. Matarese G, De Rosa V. Ob-Stopping Obesity, Metabolic and Immune-Mediated Disorders. Structure 2012; 20: 385-7.
68. Couturier C, Jockers R. Activation of the leptin receptor by a ligand-induced conformational change of constitutive receptor dimmers. J Biol Chem 2003; 278: 26604-11.
69. Mistrík P, Moreau F, Allen JM. BiaCore analysis of leptin-leptin receptor interaction: evidence for 1: 1 stoichiometry. Anal Biochem 2004; 327: 271-7.
70. Mancour L, Daghestani H, Dutta S et al. Ligand-Induced Architecture of the Leptin Receptor signaling complex. J Mol Cell 2012; 48: 651-5.
71. Xu Y, Kershaw NJ, Luo CS, et al. Crystal structure of the entire ectodomain of gp130: insights into the molecular assembly of the tall cytokine receptor complexes. J Biol Chem 2010; 285: 21214-8.
72. Huyton T, Zhang JG, Luo CS, et al. An unusual cytokine: Igdomain interaction revealed in the crystal structure of leukemia inhibitory factor LIF in complex with the LIF receptor. Proc Natl Acad Sci USA 2007; 104: 12737-42.
73. Skiniotis G, Lupardus PJ, Martick M, Walz T, Garcia KC. Structural organization of a full-length gp130/LIF-R cytokine receptor transmembrane complex Mol Cell 2008; 31: 737-48.
74. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. Hexameric structure and assembly of the interleukin-6/IL-6 alphareceptor/gp130 complex Science 2003; 300: 2101-4.
75. Haglund E, Sulkowska J, Zhao H, et al. The unique cysteine knot regulates the pleiotropic hormone leptin. Plos one 2012; 7: e45654.
76. Narcis Fernandez-Fuentes JZ, Andras F. ArchPRED: a template based loop structure prediction server Nucleic Acids Res 2006; 34 (Web Server issue): W173-6.
77. Noel JK, Whitford PC, Sanbonmatsu KY, Onuchic JN. SMOG@ctbp: simplified deployment of structure-based models in GROMACS. Nucleic Acids Res 2010; 38: W657-661.
78. Van Der Spoel D, Lindahl E, Hess B, et al. GROMACS: fast, flexible, and free. J Comput Chem 2005; 26: 1701-18.
79. Niv-Spector L, et al. Mapping leptin-interacting sites in recombinant leptin-binding domain (LBD) subcloned from chicken leptin receptor. Biochem J 2005; 290: 475-84.
80. Raver N, Gertler A, Vardy E, et al. Comparison of R128Q mutations in human, ovine, and chicken leptins. Gen Comp Endocrinol 2002; 126: 52-8.
81. Niv-Spector L, Gonen-Berger D, Gertler A, et al. Identification of the hydrophobic strand in the A-B loop of leptin as major binding site III: implications for largescale preparation of potent recombinant human and ovine leptin antagonists. Biochem J 2005; 391: 221-30.
82. Salomon G, Niv-Spector L, Gussakovsky EE, Gertler A. Largescale preparation of biologically active mouse and rat leptins and their L39A/D40A/F41A muteins which act as a potent antagonists Protein Expr Purif 2006; 47: 128-36.
83. Ramos MP. Leptin serves as an upstream activator of an obligatory signaling cascade in the embryo-implantation process. Endocrinology 2005; 146: 694-701.
84. Gonzalez RR, Rueda BR, Ramos MP, et al. Leptin-induced increase in leukemia inhibitory factor and its receptor by human endometrium is partially mediated by interleukin 1 receptor signaling. Endocrinology 2004; 145: 3850-7.
85. Gonzalez RR, Chefils S, Escobar M, et al. Leptin Signaling Promotes the Growth of Mammary Tumors and Increases the Expression of Vascular Endothelial Growth Factor VEGF and Its Receptor Type Two VEGF-R2. J Biol Chem 2006; 281: 26320-8.
86. Otvos L, Terrasi M, Cascio S, et al. Development of a pharmacologically improved peptide agonist of the leptin receptor. Biochim Biophys Acta 2008; 1783: 1745-54.
87. Knappe D, Otvos L, De Pascali F, et al. Drug developmenttargeted screening of leptin agonist glycopeptides. Int J Pept Res Ther 2008; 14: 247-54.
88. Grasso P, Leinung MC, Ingher SP, Lee DL. In vivo effects of leptin-related synthetic peptides on body weight and food intake in female ob/ob mice: localization of leptin activity to domains between amino acid residues 106-140. Endocrinology 1997; 138: 1413-18.
89. Kovalszky I, Surmacsz E, Otvos L Leptin-based glycopeptides induces weight loss and simultaneously restores fertility in animal models. Diabetes, Obesity and Metabol 2010; 12: 393-402.
90. Grasso P. Novel approaches to the treatment of obesity and type 2 diabetes mellitus: Bioactive leptin-related synthetic peptide analogs. Rec Pat on Endocrine Metabol Immune Drug Disc 2011; 5: 163-75.
91. Chan J, Roth J, Weyer C. It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development. J Investig Med 2009; 57: 777-83.
92. Tutone M, Pantano L, Lauria A, Almerico AM. In the search of leptin agonists as anti-obesity drugs: protein/protein docking, molecular dynamics, and virtual screening. Chem Biol Drug Des in press.